REVB NASDAQ
Revelation Biosciences, Inc.
1W: +3.8%
1M: -6.0%
3M: -22.1%
YTD: -66.5%
1Y: -88.4%
3Y: -99.9%
5Y: -100.0%
$1.09
+0.06 (+5.83%)
Weekly Expected Move ±6.2%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$4.3M
52W Range0.875-32.256
Volume30,808
Avg Volume82,370
Beta-0.14
Dividend—
Analyst Ratings
Company Info
CEOJames Rolke
Employees8
SectorHealthcare
IndustryBiotechnology
IPO Date2020-11-17
Websiterevbiosciences.com
4660 La Jolla Village Drive
San Diego, CA 92122
US
San Diego, CA 92122
US
650 800 3717
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Latest News
Revelation Biosciences GAAP EPS of -$2.71
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Revelation Biosciences reports FY results
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Rolke James | F-InKind | 10,115 | $1.13 | 2026-04-30 |
| Zygmont Chester Stan | F-InKind | 13,285 | $1.10 | 2026-04-30 |
| Zygmont Chester Stan | F-InKind | 13,100 | $1.65 | 2026-02-04 |
| ROPER JESS | F-InKind | 1,591 | $1.85 | 2026-02-03 |
| Chawla Lakhmir S | F-InKind | 2,261 | $1.85 | 2026-02-03 |